To substantiate findings from enrichment analysis, we validated increased downregulation of a panel of MYC target genes, including CDC45, MYC, LDHA, RFC4, and MAD2L1 [58,59,60,61], and E2F target genes, including CHEK1, DSCC1, DEPDC1, MMS22L, TOP2A, and MAD2L1 [62,63,64,65,66,67], in BRD9 KD plus pomalidomide-treated MM cells. This evidence concerns the gene MAD2L1 and Miyoshi myopathy.